Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real‐life data from a single centre

L Huseynova Terzi, N Akdogan… - … Journal of Clinical …, 2021 - Wiley Online Library
Abstract Background/Aim Rituximab (RTX) and intravenous human immunoglobulin (IVIG)
have been shown to be effective in the treatment of autoimmune bullous diseases (ABD) …
被引用次数：1 相关文章

Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre.

N Akdogan, N Atakan - International Journal of Clinical Practice, 2021 - europepmc.org
Methods Data of 33 patients with ABD [PV (93.9%)], including clinical response to treatment,
steroid cessation time, time to CR off and relapse, were recruited from medical charts …

Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real‐life data from a single centre.

L Huseynova Terzi, N Akdogan… - … Journal of Clinical …, 2021 - search.ebscohost.com
Abstract Background/Aim: Rituximab (RTX) and intravenous human immunoglobulin (IVIG)
have been shown to be effective in the treatment of autoimmune bullous diseases (ABD) …

Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre

L Terzi, N AKDOĞAN… - INTERNATIONAL …, 2021 - avesis.hacettepe.edu.tr
Background/Aim Rituximab (RTX) and intravenous human immunoglobulin (IVIG) have
been shown to be effective in the treatment of autoimmune bullous diseases (ABD), mainly …

Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre

LH Terzi, N Akdogan… - … journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Background/aim Rituximab (RTX) and intravenous human immunoglobulin (IVIG) have been
shown to be effective in the treatment of autoimmune bullous diseases (ABD), mainly …